The Texas Healthcare and Bioscience Institute (THBI) recently announced a series of high-impact topics that it plans to raise as part of its statewide Texas Healthcare and Bioscience Summit, which will tackle wide-ranging healthcare and biotech industry subjects that are impacting Texas residents and the biotech industry alike.
The event, which is set to take place in Austin, Texas on June 4-5, 2014, will wade into controversial issues such as President Obama’s premiere legislative victory, the Affordable Care Act — more commonly known as Obamacare — and the future of the Medicaid program. Considering that Texas has contributed 733,757 new Obamacare enrollments for the rollout of the program, a 13% increase in insurance rates of the nearly 6 million still uninsured, according to a THBI press release, the Summit intends to pose tough questions on the future viability of the healthcare overhaul in Texas. Of particular concern is whether or not Texas will be able to ensure that key demographics, such as young adults and Hispanics — among the most disproportionately uninsured in Texas — will be effectively registered.
Other questions, such as “what still needs to be done for individuals who do not qualify for Medicaid?” will also be broached at the Summit, given that there are serious concerns as to whether or not healthcare providers, pharmaceutical companies, and manufacturing companies are properly prepared for increased demand in Medicaid.
The Summit will also look to challenge the Texas biotech industry to work with the state government to continue to develop new ways to attract business and commerce in the biotech and life sciences industries. While there’s no doubt that Texas is one of the most business-friendly states in the United States today, an ever-changing governmental landscape and new reforms on funding will necessarily lead to new approaches to attracting the best and brightest biotech talent to the Lone Star State.
Tom Kowalski, President and CEO of THBI, characterized the upcoming Summit as an opportunity for the biotech and life sciences industries to acknowledge the short, medium, and long term challenging facing Texas, and how to overcome them: “This conference focuses on the changing, innovative landscape in Texas, but the burning question is: How will the landscape in the Texas Life Science industry look in the decade to come?” he asked. “Leadership changes in the State Legislature coupled with the implementation of the Affordable Care Act may have profound effects on how we nurture and grow our industry to remain competitive nationally and internationally. This is a must attend event.”
The Texas Healthcare and Bioscience Summit is set to take place in Austin, Texas at the Renaissance Hotel. Tickets are $325 for the summit and $100 for the Luminary Dinner. To register, visit www.thbi.com.